Liraglutide is a GLP-1 analog used in the management of type 2 diabetes mellitus, prevention of cardiovascular complications associated with diabetes, and obesity. Victoza contains liraglutide, a synthetic analog of human glucagon-like peptide-1(GLP-1) and acts as a GLP-1 receptor agonist.
- Mechanism
- Curator reviewed
Liraglutide is an acylated synthetic glucagon-like peptide-1 analog. Liraglutide is an agonist of the glucagon-like peptide-1 receptor which is coupled to adenylate cyclase. The increase in cyclic AMP stimulates the glucose dependant release of insulin, inhibits the glucose dependant release of glucagon, and slows gastric emptying to increase control of blood sugar.
- Primary indication
- Saxenda, a formulation of liraglutide intended for weight loss, is indicated as an adjunct to diet and exercise for chronic weight management in adult patients who are obese (BMI≥30 kg/m2), or who are overweight (BMI≥27...Curator reviewed · 6 structured indications
- Formula / weight
- C172H265N43O51 · 3751.2 Da
- First approval
- Canada, 2010 · United States, 2010 · European Union, 2016
- Also known as
- Liraglutide recombinant
- Code names
- 4P-004 · NN-2211 · NN-9924 · NNC 90-1170
- Brand names
Resolves to
What you can answer from here — as of May 26, 2026
Which drugs share a target with Liraglutide, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account